Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

NCT05764941 · clinicaltrials.gov ↗

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Inetetamab
DRUG: Pyrotinib
DRUG: Vinorelbine

Sponsor

The First Affiliated Hospital with Nanjing Medical University